The FDA recommends semaglutide for weight loss if you meet one of the following criteria: Have a body mass index (BMI) of 27kg/m2 or greater and at least one weight-related condition, such as high blood pressure, Type 2 diabetes or high cholesterol Have a BMI of 30kg/m2 or greater Avoid semaglutide if you have: History of medullary thyroid cancer History of gallbladder disease History of pancreatitis Multiple endocrine neoplasia syndrome type 2 (MEN2) Conclusion: Semaglutide for Weight Loss Semaglutides effectiveness in reducing body fat can be attributed to its impact on appetite regulation, gastric emptying, and energy expenditure
Carnitine plays an essential role in the way that mitochondria use fats for fuel, and the study showed that mice deficient in a carnitine transporter, SLC25A45, didnt lose weight as easily on a GLP-1 RA medication.[ref] Related article: Carnitine genes GLP-1 Beyond Weight Loss: Heart Disease, Alzheimers, Cancer, and Immunity Recent studies show that the benefits of GLP-1 RA medications extend beyond weight loss
However, at the recommendation of the FDA, patients with diabetes were included to support broader context of use for this questionnaire
adverse side effects are observed with greater frequency at doses of IN PT-141 of over 10 mg, such as doses of 20 mg of IN PT-141
